SCHEMBL23723367

SCHEMBL23723367

C#CCCCOc1cc(OCCCC#C)cc(-c2cn(Cc3cccc(SC/C(F)=C/CNC(=O)O)c3)nn2)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CD74 P04233 2/20 0.36
MIF P14174 2/20 0.36
HDAC1 Q13547 4/20 0.35
HDAC2 Q92769 4/20 0.35
HDAC10 Q969S8 4/20 0.35
HDAC8 Q9BY41 4/20 0.35
HDAC6 Q9UBN7 4/20 0.35
HDAC3 O15379 3/20 0.35
HDAC4 P56524 2/20 0.35
HDAC7 Q8WUI4 2/20 0.35
HDAC11 Q96DB2 2/20 0.35
HDAC9 Q9UKV0 2/20 0.35
HDAC5 Q9UQL6 2/20 0.35
EGLN1 Q9GZT9 9/20 0.35
SIRT2 Q8IXJ6 1/20 0.34
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23723370 1.00 CD74 (0.36) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL30633627 0.91 CD74 (0.35) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL23745975 0.91 CD74 (0.35) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL23723238 0.86 CD74 (0.36) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL23723237 0.86 CD74 (0.36) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL23723295 0.83 CD74 (0.44) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL23723299 0.83 CD74 (0.44) CD74MIFHDAC1HDAC2HDAC10
SCHEMBL23723377 0.79 MAOB (0.36) HDAC1HDAC2HDAC10HDAC8HDAC6
SCHEMBL23723374 0.79 MAOB (0.36) HDAC1HDAC2HDAC10HDAC8HDAC6
SCHEMBL23745974 0.77 CD74 (0.35) CD74MIFHDAC1HDAC2HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230349907-A1 BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2023-11-02 US disclosed
WO-2021155439-A1 BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF PHARMAXIS LTD. (AU) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230349907-A1 BIOPROBES FOR LYSYL OXIDASES AND USES THEREOF MAOB, LOX, LPO CD74 2182/4885MIF 3666/4885HDAC1 2419/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.